An open label, non-randomized, multicenter phase 1/2b study investigating safety and efficacy of PQR309 and eribulin combination in patients with locally advanced or metastatic HER2 negative and triple-negative breast cancer
Phase of Trial: Phase I/II
Latest Information Update: 02 May 2017
At a glance
- Drugs Eribulin (Primary) ; PQR 309 (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors PIQUR Therapeutics
- 20 Sep 2016 Status changed from not yet recruiting to recruiting.
- 30 Mar 2016 Status changed from planning to not yet recruiting as per ClinicalTrials.gov record.
- 19 Feb 2016 New trial record